The data significantly de-risk IMA203CD8 as a potential tumor-agnostic therapy. Watch for expansion cohorts in uterine and ovarian cancers, and the planned pediatric IIT in 1H 2027. The strong ORR/cORR in heavily pretreated patients supports accelerated development — any partnership or regulatory milestone would be a further catalyst.
Price Chart
Executive Summary
Immatics N.V. released updated Phase 1 data for its IMA203CD8 PRAME-directed TCR T-cell therapy, showing a 51% objective response rate (ORR) and 41% confirmed ORR across 90 evaluable patients with heavily pretreated advanced solid tumors. The therapy demonstrated a manageable safety profile with no IMA203CD8-related Grade 5 events, and the maximum tolerated dose was not reached. The data support clinical proof-of-concept across multiple tumor types, with particularly encouraging activity in gynecologic cancers at higher doses (60% ORR, 55% cORR).
Key Facts
- 51% ORR (46/90) and 41% confirmed ORR (36/87) across all dose levels and tumor types
- 83% tumor reduction (71/86) in evaluable patients; 82% disease control rate at week 6
- In gynecologic cancers at clinically relevant doses (≥DL4c): 60% ORR (12/20), 55% cORR (11/20)
- Median duration of response in gynecologic cancers: 8.4 months; median PFS: 5.8 months; median OS not reached at 7.8 months follow-up
- No IMA203CD8-related Grade 5 events; MTD not reached with doses up to 12.5 billion cells
- Phase 1a dose escalation complete; enrolling uterine cancer patients; Phase 1/2 IIT in pediatric cancers planned for 1H 2027
Financial Impact
Positive catalyst for IMTX stock; strong Phase 1 efficacy data across multiple solid tumors supports pipeline value and potential registration-enabling trials
Risk Factors
- Phase 1 data are preliminary and subject to further quality checks and source data verification
- Durability data in gynecologic cancers are early (median follow-up 6.0 months); longer follow-up needed
- Competitive landscape includes other TCR-T and CAR-T therapies targeting solid tumors
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0000950103-26-016061 |
| Document: dp255331_6k.htm | 0000950103-26-016061 |
| Document: 0000950103-26-016061-index-headers.html | 0000950103-26-016061 |
| Document: 0000950103-26-016061-index.html | 0000950103-26-016061 |
| Document: 0000950103-26-016061.txt | 0000950103-26-016061 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+5 | — | — |
Oct 24, 2026 2d ago | Press Release | $7.31 | awaiting T+5 | — | $7.18 (−1.85%) |
Oct 23, 2026 3d ago | 6-K | $7.60 | awaiting T+5 | — | $7.18 (−5.59%) |
Aug 27, 2026 8w ago | Insider Buy | $9.45 $9.56 | ▲ +1.16% | ▲ +1.05% | $7.18 (−24.07%) |
Aug 26, 2026 8w ago | 6-K | $9.36 $9.46 | ▼ −1.07% | ▼ −0.80% | $7.18 (+23.34%) |
Aug 18, 2026 9w ago | 6-K | $9.09 $9.24 | ▲ +1.65% | ▲ +1.85% | $7.18 (−21.07%) |
Aug 18, 2026 9w ago | Press Release | $9.09 $9.24 | ▲ +1.65% | ▲ +1.85% | $7.18 (−21.07%) |
Jun 2, 2026 20w ago | 6-K | $10.04 $9.16 | ▼ −8.76% | ▼ −5.80% | $7.18 (−28.54%) |
Jun 1, 2026 21w ago | 6-K | $11.14 $9.79 | ▼ −12.12% | ▼ −9.37% | $7.18 (−35.59%) |
Jun 1, 2026 21w ago | Press Release | $11.14 $9.79 | ▼ −12.12% | ▼ −9.37% | $7.18 (−35.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers